Sanofi: FDA grants priority review to treatment for hemophilia A









Agefi – Dow Jones |

SANOFI

Sanofi: FDA grants priority review to treatment for hemophilia A | Photo credits: Sanofi Pasteur/Vincent Moncorgé

PARIS (Agefi-Dow Jones)–The pharmaceutical company Sanofi announced on Tuesday that the American health authority, the Food and Drug Administration (FDA), had granted priority review procedure to its treatment efanesoctocog alpha for the treatment of hemophilia A.

This priority review concerns data from a phase III study. The decision on a possible commercialization on the American treatment market should take place on February 28, 2023, Sanofi said in a press release.

-Francois Schott, Agefi-Dow Jones; +33 (0)1 41 27 47 92; [email protected] ed: VLV

Agefi-Dow Jones The financial newswire

Dow Jones Newswires

August 30, 2022 01:53 ET (05:53 GMT)







Source link -90